PhageLine

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss Phage-antibiotic synergy to combat multidrug-resistant strains of Gram-negative ESKAPE pathogens by examining a recent paper by Morris et al. in Scientific Reports. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the episode's contents.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss the impact of microplastics on bacteriophage activity in aqueous environments by talking about a recent paper from Ochirbat et al. in the Journal of Physical Chemistry. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the episode's contents.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss the bacteriophage potential of SARS-CoV-2 in human gut microbiota by talking about a recent paper by Petrillo et al in F1000. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the episode's contents.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss a method for the targeted discovery of bacteriophages by co-culture, called Phage DisCo, which was recently published in mSystems by Eleanor Rand and her colleagues at Harvard University. Usually, I would say "have fun" here; however, there is also a dark side to this episode: all five federal grants that supported different parts of this work were part of the mass termination of Harvard grants three weeks ago, as confirmed by principal investigator Michael Baym.

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the contents of the episode.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss the in vitro genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii by discussing a recent paper by Sherif et al. in Scientific Reports. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the contents of the episode.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss personalized inhaled bacteriophage therapy for treating multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis by talking about a recent publication by Chan et al in Nature Medicine. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the contents of the episode.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss the effects of Phage–phage competition and biofilms on interactions between two virulent bacteriophages and Pseudomonas aeruginosa, which were recently published by Bürkle et al. in ISME. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the contents of the episode.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will discuss PhageDPO, a machine-learning-based computational framework for identifying phage depolymerases, recently published by Viera et al. in Elsevier's Computers in Biology and Medicine. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the contents of the episode.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will focus on the differences in phage recognition and immunogenicity in humans unraveled in a recent paper by Le et al. in the European Journal of Immunology. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the contents of the episode.

Hello and welcome to PhageLine - your line to everything phage.

This week, we will focus on optimizing phage engineering through an accelerated evolution platform by discussing a recent paper by Favor et al. from Nextbiotics Inc. in Scientific Reports. Have fun!

This episode was generated using artificial intelligence. An infectious disease researcher reviewed the contents of the episode.